Tissue plasminogen activator (t-PA) and its inhibitor (PAI) were assessed in venous blood drawn before and after venous occlusion (bvo, avo) for 33 patients with Raynaud's phenomenon (RP), 14 with primary RP (PRP), 9 with suspected secondary RP (SSRP), and 10 with definite collagen disease and secondary RP (SRP). There were significant differences in PAI values avo between PRP (and controls), SSRP, and SRP. PAI activity decreased significantly avo only in controls and in PRP, and there was significant t-PA antigen elevation avo in the same groups. In addition, since PAI is neutralized by activated protein C (PC), both PC antigen and PC activity were assessed avo and bvo. PC Ag remained unchanged in all groups, with PC activity significantly lower than controls in SRP and SSRP. Finally the authors looked for interference of anticardiolipin antibod ies (ACA) and lupus-like anticoagulant (LAC) with the PC system in collagen disease-associated RP. Specific IgG ACA were found in only 1 patient with SRP. In conclusion, there is an endothelial derangement, involving t-PA release and PAI, in SSRP and SRP patients. The reduced PC activity in these latter groups appears to be due to increased PAI influence rather than to ACA/LAC.
Get full access to this article
View all access options for this article.
References
1.
Robertson D. , Oates JA: Variant angina and Raynaud's phenomenon . Lanceti:452, 1974.
2.
Miller D., Waters DD, Warnica W., et al: Is variant angina the coronary manifestation of a generalized vasospastic disorder?N Engl J Med304:763-766, 1981.
3.
Seybold JR, Harris JN: Plasma beta-thromboglobulin in the differential diagnosis of Raynaud's phenomenon . J Rheumatol12:99-103, 1985.
4.
Cimminiello C. , Milani M. Uberti T, et al: Differential diagnosis of Raynaud's phenomenon: The role of t-PA and PAI. Fibrinolysis2 (S 1): abstr 231, 1988.
5.
Sakata Y., Curriden S., Lawrence D., et al: Activated pprotein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA82:1121-1125, 1985 .
6.
Fort JC, Cowchock FS, Abruzzo JL, et al: Anticardiolipin antibodies in patients with rheumatic diseases . Arthritis Rheum30:672-760, 1987.
7.
Freyssenet JM , Cazenave JP: Lupus like anticoagulants, modulation of the protein C pathway and thrombosis. Thromb Haemost58:679-681, 1987.
8.
Wouda AA: Raynaud phenomenon. Photoelectric plethysmography of the fingers of persons with and without Raynaud's phenomenon during cooling and warming up . Acta Med Scand201:519-523, 1987.
9.
Maricq HR: Widefield capillary microscopy: Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum24:1159-1165, 1981.
10.
Bergsdorf N. , Nilsson T., Wallen P.: An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied patients with thromboembolic disease. Thromb Haemost50:740-744, 1983.
11.
Chmielewska J., Wiman B.: Determination of tissue plasminogen activator and.its "fast" inhibitor in plasma. Clin Chem32:482-448, 1986.
12.
Boyer C., Rothsmild C., Wolfe M., et al: A new method for the estimation of protein C by ELISA. Thromb Res36:579-589, 1984.
13.
Nicham F., Martinoli JL: Amidolytic determination of antiactivated protein C activity in plasma . Thromb Haemostas58:(S1):abstr 1517, 1987.
14.
Rosner E., Pauzner R., Lusky A., et al: Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemostas57:144-147, 1987.
15.
Nilsson IM, Ljungner H., Tengborn L.: Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator increased concentration of plasminogen activator inhibitor. Br Med J290:1453-1456, 1985.
16.
Juhan-Vague IE , Aillaud MF, De Cook F., et al: The fastacting inhibtor of tissue type plasminogen activator is an acute phase reactant protein . In: Progress in Fibrinolysis, vol 7, ed. by Davidson JF, Donati MBCoccheri S.Edinburgh: Churchill Livingstone, 1985, p 146.
17.
Hamsten A., Walldius G., Szamosi A., et al: Plasminogen activator inhibitor in plasma; risk factor for recurrent myocardial infarction. Lancetii:3-9, 1987.
18.
Wiman B., Ljungberg B., Chmielewska J., et al: The role of the fibrinolytic system in deep vein thrombosis . J Lab Clin Med105:265-270, 1985.
19.
Zoumboulakis J., Koustus G., Kokotsakis J., et al: t-PA release after venous occlusion in patients with Raynaud's syndrome. Tenth International Congress onThrombosis, Athens, Greece, 1988 (abstract).
20.
Jarret Pem, Morland M., Browse NL: Treatment of Raynaud's phenomenon by fibrinolytic enhancement. Br Med J2:523-525, 1978.
21.
Stegnar M., Keber D., Pentek M., et al: Age and sex differences in resting and postocclusion values of tissue plasminogen activator in a healthy population. Fibrinolysis2(S2): 121-122, 1988.
22.
Kahaleh MB, Osborn I., Le Roy EC: Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and Raynaud's phenomenon. Ann Intern Med94:482-484, 1981.
Bern MM, Cannasi MP, Horton J., et al: Changes of fibrinolysis and factor VIII coagulant, antigen and ristocetin cofactor in diabetes mellitus and atherosclerosis. Thromb Res19:831-838, 1980.
27.
Rodnan GP, Myerowitz RL, Justh GO: Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine59:393-408, 1980.
28.
Speiser W., Anders E., Preissner KT, et al: Differences in coagulant and fibrinolytic activities of cultured human endothelial cells derived from omental tissue microvessels and umbilical veins. Blood69:964-967, 1987.
29.
Jordan JM, Allen NP, Pizzo SV: Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. Am J Med82:397-400, 1987.
30.
Awada H., Barlowatz Meimon G, Dougados M., et al: Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis. J Lab Clin Med111:229-236, 1988.
31.
Van Hinsbergh VWM, Bertina RM, Van Wijngaarden A, et al: Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium . Blood65:444-451, 1985.
32.
Kruithoff Eko : Plasminogen activator inhibitor type 1: Biochemical, biological and chemical aspects. Fibrinolysis2 (S2):59-70, 1988.
33.
Suzuki K., Nishioka J., Hashimoto S.Protein C inhibitor. J Biol Chem258:163-168, 1983.
34.
Heeb MJ, Espana F., Geiger M., et al: Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3. J Biol Chem15813-15815, 1987.
